Literature DB >> 24390803

Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas.

Shuai Wang1, Shengkui Lu, Shaomei Geng, Shucheng Ma, Zhaohui Liang, Baohua Jiao.   

Abstract

MicroRNA-206 (miR-206) has been proved to function as a tumor suppressor in several types of human malignant cancers. More recently, it has been demonstrated that the ectopic expression of miR-206 significantly inhibited the proliferation and promoted apoptosis at the early stages in glioma cell U343. In order to investigate the clinical significance of miR-206 expression in human astrocytoma, quantitative real-time polymerase chain reaction (qRT-PCR) analysis was used to characterize the expression patterns of miR-206 in 108 astrocytoma and 20 normal brain tissues. As the results, the expression levels of miR-206 in astrocytoma tissues were significantly lower than those in normal brain tissues (P < 0.001). Additionally, the decreased expression of miR-206 in astrocytoma was significantly associated with advanced pathological grade (P = 0.008), low Karnofsky performance score (KPS, P = 0.02), and large tumor size (P = 0.01). Moreover, Kaplan-Meier survival and Cox regression analyses showed that low miR-206 expression (P < 0.001) and advanced pathological grade (P = 0.02) were independent factors predicting poor prognosis for astrocytomas. In conclusion, this is the first report of the differential expression of miR-206 in human astrocytoma tissues. MiR-206 could be a valuable marker of astrocytoma progression and low miR-206 expression is associated with poor overall survival in patients with malignant astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390803     DOI: 10.1007/s12253-013-9701-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

1.  Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo.

Authors:  Arti B Gaur; Susan L Holbeck; Nancy H Colburn; Mark A Israel
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  miR-206 and -486 induce myoblast differentiation by downregulating Pax7.

Authors:  Bijan K Dey; Jeffrey Gagan; Anindya Dutta
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

3.  Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERα-positive endometrioid adenocarcinoma.

Authors:  Xiaoyue Chen; Qin Yan; Shuangdi Li; Long Zhou; Huajing Yang; Yixia Yang; Xuelian Liu; Xiaoping Wan
Journal:  Cancer Lett       Date:  2011-09-21       Impact factor: 8.679

4.  MiR-206 regulates neural cells proliferation and apoptosis via Otx2.

Authors:  Rui Wang; Yi Hu; Ge Song; Chan Juan Hao; Yi Cui; Hong-Fei Xia; Xu Ma
Journal:  Cell Physiol Biochem       Date:  2012-04-03

Review 5.  MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease.

Authors:  W H Davin Townley-Tilson; Thomas E Callis; DaZhi Wang
Journal:  Int J Biochem Cell Biol       Date:  2009-03-14       Impact factor: 5.085

6.  Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma.

Authors:  Mitsuru Miyachi; Kunihiko Tsuchiya; Hideki Yoshida; Shigeki Yagyu; Ken Kikuchi; Akiko Misawa; Tomoko Iehara; Hajime Hosoi
Journal:  Biochem Biophys Res Commun       Date:  2010-08-07       Impact factor: 3.575

7.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

Review 8.  The 2007 WHO classification of tumors of the central nervous system - what has changed?

Authors:  Audrey Rousseau; Karima Mokhtari; Charles Duyckaerts
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

9.  MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Authors:  E Missiaglia; C J Shepherd; S Patel; K Thway; G Pierron; K Pritchard-Jones; M Renard; R Sciot; P Rao; O Oberlin; O Delattre; J Shipley
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

10.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Authors:  Naoto Kondo; Tatsuya Toyama; Hiroshi Sugiura; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

View more
  6 in total

1.  Decreased expression of microRNA-107 predicts poorer prognosis in glioma.

Authors:  Yuchen Ji; Yujun Wei; Jianyong Wang; Qiang Ao; Kai Gong; Huancong Zuo
Journal:  Tumour Biol       Date:  2015-01-18

2.  MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.

Authors:  Qing-yong Chen; De-min Jiao; Yu-quan Wu; Jun Chen; Jian Wang; Xia-li Tang; Hao Mou; Hui-zhen Hu; Jia Song; Jie Yan; Li-jun Wu; Jianyan Chen; Zhiwei Wang
Journal:  Oncotarget       Date:  2016-04-05

3.  Propofol Inhibits the Migration and Invasion of Glioma Cells by Blocking the PI3K/AKT Pathway Through miR-206/ROCK1 Axis.

Authors:  Dongmei Wang; Tao Yang; Junqi Liu; Yafei Liu; Na Xing; Juan He; Jianjun Yang; Yanqiu Ai
Journal:  Onco Targets Ther       Date:  2020-01-14       Impact factor: 4.147

4.  MicroRNA-206 has a bright application prospect in the diagnosis of cases with oral cancer.

Authors:  Lili Wang; Hongguang Song; Shiming Yang
Journal:  J Cell Mol Med       Date:  2021-08-21       Impact factor: 5.310

Review 5.  Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128.

Authors:  Yogita K Adlakha; Neeru Saini
Journal:  Mol Cancer       Date:  2014-02-21       Impact factor: 27.401

Review 6.  Prognostic Value and Clinicopathological Features of MicroRNA-206 in Various Cancers: A Meta-Analysis.

Authors:  Rongqiang Liu; Shiyang Zheng; Shengjia Peng; Yajie Yu; Jianwen Fang; Siwen Tan; Fan Yao; Zhihua Guo; Yi Shao
Journal:  Biomed Res Int       Date:  2020-10-20       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.